Catalyst Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Catalyst Pharmaceuticals Inc. following an internal realignment.
NASDAQ
State Street Corporation has reported a 5.2% beneficial ownership stake in Catalyst Pharmaceuticals Inc. common stock as of September 30, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 13.9% Stake in Catalyst Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 13.9% of Catalyst Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Deerfield Entities Maintain Passive Stake in Catalyst Pharmaceuticals, Disclosing 2.63% Ownership
Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have jointly filed an amendment to their Schedule 13G, disclosing a continued passive beneficial ownership of 2.63% in Catalyst Pharmaceuticals, Inc.